CSIMarket



Biogen Inc   (BIIB)
Other Ticker:  
 
 

BIIB's Operating Income Growth by Quarter and Year

Biogen Inc 's Operating Income results by quarter and year




BIIB Operating Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 587.10 -330.70 1,777.70
III Quarter September - 794.00 1,086.40 1,806.30
II Quarter June - 485.70 1,974.50 1,955.90
I Quarter March 610.70 973.90 1,819.90 1,502.70
FY   610.70 2,840.70 4,550.10 7,042.60



BIIB Operating Income first quarter 2022 Y/Y Growth Comment
Biogen Inc reported fall in Operating Income in the first quarter 2022 by -37.29% to $ 610.70 millions, from the same quarter in 2021.
The drop in the first quarter 2022 Biogen Inc 's Operating Income compares unfavorably to the Company's average Operating Income growth of 5.46%.

Looking into first quarter 2022 results within Biotechnology & Pharmaceuticals industry 19 other companies have achieved higher Operating Income growth. While Biogen Inc ' s Operating Income drop of -37.29% ranks overall at the positon no. 1841 in the first quarter 2022.

Explain Operating Income growth


BIIB Operating Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - 23.19 %
III Quarter September - -26.91 % -39.85 % 6.4 %
II Quarter June - -75.4 % 0.95 % 61.22 %
I Quarter March -37.29 % -46.49 % 21.11 % -2.09 %
FY   - -37.57 % -35.39 % 19.6 %

Financial Statements
Biogen Inc 's first quarter 2022 Operating Income $ 610.70 millions BIIB's Income Statement
Biogen Inc 's first quarter 2021 Operating Income $ 973.90 millions Quarterly BIIB's Income Statement
New: More BIIB's historic Operating Income Growth >>


BIIB Operating Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - -26.06 % - -1.58 %
III Quarter September - 63.48 % -44.98 % -7.65 %
II Quarter June - -50.13 % 8.49 % 30.16 %
I Quarter March 4.02 % - 2.37 % 4.13 %
FY (Year on Year)   - -37.57 % -35.39 % 19.6 %




Operating Income first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #20
Healthcare Sector #140
Overall #1841

Operating Income Y/Y Growth Statistics
High Average Low
106.48 % 5.46 % -50.43 %
(Sep. 30, 2006)   (June 30. 2006)
Operating Income first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #20
Healthcare Sector #140
Overall #1841
Operating Income Y/Y Growth Statistics
High Average Low
106.48 % 5.46 % -50.43 %
(Sep. 30, 2006)   (June 30. 2006)

Operating Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Biogen Inc 's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
340.82 % 10.67 % -54.29 %
(Dec. 31, 2005)   (Sep. 30, 2005)


BIIB's I. Quarter Q/Q Operating Income Comment
Biogen Inc achieved in the I. Quarter 2022 below company average Operating Income growth of 4.02% quarter on quarter, to $ 610.70 millions.

Even if the I. Quarter 2022 Biogen Inc 's Operating Income quarter on quarter growth was below the regular , this was yet good news, as the current expension, eclipses the % surge in the same quarter a year ago

Within Biotechnology & Pharmaceuticals industry 8 other companies have achieved higher Operating Income quarter on quarter growth. While Biogen Inc 's Operating Income growth quarter on quarter, overall rank is 817.


Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #9
Healthcare Sector #54
Overall #817
Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #9
Healthcare Sector #54
Overall #817
Operating Income Q/Q Growth Statistics
High Average Low
340.82 % 10.67 % -54.29 %
(Dec. 31, 2005)   (Sep. 30, 2005)


BIIB's I. Quarter Q/Q Operating Income Comment
Biogen Inc achieved in the I. Quarter 2022 below company average Operating Income growth of 4.02% quarter on quarter, to $ 610.70 millions.

I. Quarter 2022 Biogen Inc 's performance were paradoxical, albeit beneath the regular, yet it demonstrates a quite acceleration measured to the % in the I. Quarter a year ago Mathilde Lambert, market researcher wrote.

Within Biotechnology & Pharmaceuticals industry 8 other companies have achieved higher Operating Income quarter on quarter growth. While Biogen Inc 's Operating Income growth quarter on quarter, overall rank is 817.


Biogen Inc 's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Operating Income 12 Months Ending $ 2,477.50 $ 2,840.70 $ 1,922.90 $ 2,215.30 $ 3,704.10
Y / Y Operating Income Growth (TTM) -33.11 % -37.57 % -71.12 % -69.98 % -49.67 %
Year on Year Operating Income Growth Overall Ranking # 1670 # 231 # 103 # 140 # 1865
Seqeuential Operating Income Change (TTM) -12.79 % 47.73 % -13.2 % -40.19 % -18.59 %
Seq. Operating Income Growth (TTM) Overall Ranking # 1841 # 22 # 110 # 2097 # 107




Cumulative Operating Income growth Comment
Biogen Inc showed decline, but improvement compare to trailing twelve month Operating Income decrease in Dec 31 2021. If the fiscal year would end in Mar 31 2022, Biogen Inc 's annual Operating Income fall would be -33.11% year on year to $2,478 millions.

In the Healthcare sector 119 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 231 to 1670.

Operating Income TTM Q/Q Growth Statistics
High Average Low
106.48 %
5.46 %
-50.43 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 20
Healthcare Sector # 120
Overall # 1670

Operating Income TTM Y/Y Growth Statistics
High Average Low
443.68 %
31.02 %
-71.12 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 20
Sector # 140
S&P 500 # 1841
Cumulative Operating Income growth Comment
Biogen Inc showed decline, but improvement compare to trailing twelve month Operating Income decrease in Dec 31 2021. If the fiscal year would end in Mar 31 2022, Biogen Inc 's annual Operating Income drop would be -33.11% year on year to $2,478 millions.

In the Healthcare sector 119 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 231 to 1670.

Operating Income TTM Q/Q Growth Statistics
High Average Low
106.48 %
5.46 %
-50.43 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 20
Healthcare Sector # 120
Overall # 1670

Operating Income TTM Y/Y Growth Statistics
High Average Low
443.68 %
31.02 %
-71.12 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 20
Sector # 140
S&P 500 # 1841




Other Operating Income Growth
Biotechnology & Pharmaceuticals Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
BIIB's Operating Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for BIIB's Competitors
Operating Income Growth for Biogen Inc 's Suppliers
Operating Income Growth for BIIB's Customers

You may also want to know
BIIB's Annual Growth Rates BIIB's Profitability Ratios BIIB's Asset Turnover Ratio BIIB's Dividend Growth
BIIB's Roe BIIB's Valuation Ratios BIIB's Financial Strength Ratios BIIB's Dividend Payout Ratio
BIIB's Roa BIIB's Inventory Turnover Ratio BIIB's Growth Rates BIIB's Dividend Comparisons



Companies with similar Operating Income drop for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Mar 31 2022
Lemaitre Vascular Inc-0.21%$ -0.214 millions
Intuitive Surgical Inc -2.09%$ -2.087 millions
Innoviva Inc -2.21%$ -2.207 millions
Stryker Corp-2.61%$ -2.614 millions
National Research Corporation-2.69%$ -2.687 millions
Diffusion Pharmaceuticals Inc -2.77%$ -2.773 millions
Msa Safety Inc-3.11%$ -3.111 millions
Nuvasive Inc-3.28%$ -3.282 millions
Royalty Pharma Plc-4.18%$ -4.178 millions
Phibro Animal Health Corp-4.66%$ -4.659 millions
Co diagnostics Inc -4.94%$ -4.942 millions
National Healthcare Corp-6.60%$ -6.602 millions
Natus Medical Inc-7.50%$ -7.500 millions
Dexcom Inc -10.02%$ -10.022 millions
Biomx Inc -10.20%$ -10.196 millions
Pacira Biosciences inc -10.52%$ -10.516 millions
Align Technology inc -12.14%$ -12.138 millions
Lifevantage Corp-12.60%$ -12.596 millions
Tivity Health Inc -12.86%$ -12.858 millions
Rackspace Technology Inc -13.64%$ -13.636 millions
Diversified Healthcare Trust-15.19%$ -15.194 millions
Community Health Systems Inc -17.18%$ -17.178 millions
Fonar Corporation-18.88%$ -18.878 millions
Universal Health Services Inc -21.24%$ -21.244 millions
Molecular Templates Inc -21.64%$ -21.642 millions
Quest Diagnostics Inc-22.27%$ -22.273 millions
Davita Inc -23.56%$ -23.564 millions
Fulgent Genetics Inc -24.35%$ -24.348 millions
Zimmer Biomet Holdings Inc -25.30%$ -25.301 millions
Reynolds Consumer Products Inc -25.44%$ -25.439 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

DESP's Profile

Stock Price

DESP's Financials

Business Description

Fundamentals

Charts & Quotes

DESP's News

Suppliers

DESP's Competitors

Customers & Markets

Economic Indicators

DESP's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071